Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.46 |
| ▸ | CFTR | P13569 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 7/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CCR9 | P51686 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202739 | 1.00 | TLR7 (0.46) | TLR7CFTRNAMPTDHODHCYP2C9 | |
| SCHEMBL25296983 | 0.80 | MEN1 (0.48) | PTGDR2 | |
| SCHEMBL4014106 | 0.75 | CYP2D6 (0.53) | NAMPT | |
| SCHEMBL4014111 | 0.75 | CYP2D6 (0.53) | NAMPT | |
| SCHEMBL18279239 | 0.74 | CFTR (0.67) | TLR7CFTRNAMPTCYP2C9CCR9 | |
| SCHEMBL17675152 | 0.74 | SYK (0.38) | TLR7 | |
| SCHEMBL29773105 | 0.73 | CFTR (0.52) | CFTRNAMPTCYP2C9 | |
| SCHEMBL28203528 | 0.73 | CFTR (0.52) | CFTRNAMPTCYP2C9 | |
| SCHEMBL15142683 | 0.72 | SMN1; SMN2 (0.45) | TLR7CYP2C9 | |
| SCHEMBL3913503 | 0.72 | HTR6 (0.47) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274828-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150174-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2022-07-14 | — | — | WO | disclosed |